JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
137.52
-1.00 (-0.72%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close138.52
Open139.35
Bid137.54 x 800
Ask137.62 x 1200
Day's Range135.75 - 140.24
52 Week Range118.62 - 148.99
Volume9,915,841
Avg. Volume6,781,038
Market Cap366.184B
Beta (3Y Monthly)0.69
PE Ratio (TTM)25.49
EPS (TTM)5.40
Earnings DateJul 16, 2019
Forward Dividend & Yield3.60 (2.58%)
Ex-Dividend Date2019-02-25
1y Target Est145.44
Trade prices are not sourced from all markets
  • 5 Top Pharmaceutical Stocks to Buy in 2019
    Motley Foolyesterday

    5 Top Pharmaceutical Stocks to Buy in 2019

    Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.

  • The Top 10 Biotechnology Companies (JNJ, ROG.VX)
    Investopedia2 days ago

    The Top 10 Biotechnology Companies (JNJ, ROG.VX)

    Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

  • TheStreet.com2 days ago

    Be Careful With Healthcare Stocks Here

    CEO David Wichmann on his company's earnings conference call Tuesday: "Medicare For All." UNH shares had been bid up in Tuesday morning trade on the back of earnings and revenues that exceeded analyst estimates. Want to be alerted before Jim Cramer buys or sells JNJ or UNH?

  • Benzinga2 days ago

    Buyer's Remorse? OTC Stock Zoom Technologies Zooms Higher Amid Potential Buyer Confusion

    Zoom Technologies Inc (OTC: ZOOM ) traded higher by as much as 120 percent Thursday morning after popular video and audio platform Zoom Video Communications Inc (NASDAQ: ZM ) held its highly anticipated ...

  • Here Are the Key Takeaways From J&J's Q1 Earnings Report
    Zacks2 days ago

    Here Are the Key Takeaways From J&J's Q1 Earnings Report

    Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.

  • Reuters3 days ago

    Idorsia confirms 2019 spending plan as clinical trials "on track"

    Swiss biotech Idorsia said on Thursday that all four clinical trials of its late-stage drug hopefuls were "on track" as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on the projects. Idorsia founder Chief Executive Jean-Paul Clozel has Phase III studies of drugs for insomnia, rare Fabrys disease, hypertension and brain bleeding.

  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of JNJ earnings conference call or presentation 16-Apr-19 12:30pm GMT

    Q1 2019 Johnson & Johnson Earnings Call

  • Liability Issues Weigh on Johnson & Johnson
    Investopedia3 days ago

    Liability Issues Weigh on Johnson & Johnson

    Johnson & Johnson relinquished the majority of gains after a post-earnings rally, held down by baby powder liability fears.

  • Benzinga3 days ago

    Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative

    Johnson & Johnson (NYSE: JNJ ) kickstarted the large-cap pharma earnings season Tuesday with forecast-beating first-quarter results. The company narrowed its full-year earnings per share guidance but maintained ...

  • Stock Market News For Apr 17, 2019
    Zacks3 days ago

    Stock Market News For Apr 17, 2019

    Markets closed higher on Tuesday as investors welcomed a spate of healthy first quarter earnings results.

  • Investing.com3 days ago

    StockBeat - UnitedHealth Deepens Losses as Fears Over Political Risk Rise

    Investing.com - UnitedHealth Group fell deeper into the red Wednesday as analysts turned bearish on the stock in the wake of its CEO's warning on political risk.

  • 10 Best Stocks to Buy and Hold Forever
    InvestorPlace3 days ago

    10 Best Stocks to Buy and Hold Forever

    [Editor's note: This story was previously published in March 2019. It has since been updated and republished.]In a market environment that overwhelmingly encourages constant activity by investors who seemingly want to double their money every week, a discussion of stocks to buy and hold forever seems comically out of place.And yet, for better or worse, that's the mindset all of us should adopt for most of our investing capital. More often than not, the more you trade, the worse you end up doing.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt has been said (and verified) that 95% of true "day traders" -- the most aggressive and active of all market participants -- end up losing money by being too active for their own good. Conversely, the fact that Warren Buffett's favorite holding period is "forever" and how he's got a track record most investors would envy is just as telling. * 10 S&P 500 Stocks to Weather the Earnings Storm With that as the backdrop, here's a rundown of 10 stocks to buy and hold forever … or at least until something significant changes with your life plans or the companies themselves.Source: Shutterstock AT&T (T)Dividend Yield: 6.33% Year-to-date gain: 9.3%Calling a spade a spade, shares of telecom giant AT&T Inc. (NYSE:T) haven't been easy to own in a while. The stock is down 14% from its mid-2016 peak, while most other stocks are well up for the timeframe. The impasse has been an increasingly tougher wireless and broadband market. But now that plans to acquire media outfit Time Warner Inc (NYSE:TWX) look good a turnaround might have begun.If your intended timeframe really is "forever" though, a tough couple of years is nothing … particularly considering you're collecting a healthy dividend yield on your position's current value.More than that though, this is a telco name with a lot of clout, and a little more than $50 billion in the bank. And, if/when the Time Warner deal goes through, it will have yet another revenue-bearing weapon in its arsenal.Source: Shutterstock Alphabet (GOOGL, GOOG)Dividend Yield: N/A Year-to-date gain: 17.25%Fans and followers of the company will likely know that Google parent company Alphabet Inc (NASDAQ:GOOGL, NASDAQ:GOOG) beat last quarter's earnings estimate, posting $12.77 per share. What got lost in the shuffle is how operating margains fell to 21 % from last quarter's 24%. * 7 Stocks to Buy for Spring Season Growth Appreciated or not, Alphabet is a profit and revenue growth machine that has earned its spot on a list of "forever" stocks to buy. It may not always beat estimates, but it does always increase its numbers. That's because it keeps finding a way to serve as the middleman for about 70% of web searches done on desktops, and boasts being the preferred search engine for about 90% of the queries made via a mobile device.If it was going to be toppled, we'd see evidence of it by now.Source: Shutterstock 3M (MMM)Dividend Yield: 2.64% Year-to-date gain: 14.13%In an era where complicated companies are shedding disparate parts of themselves so each arm can be hyper-focused on doing one thing exceedingly well, 3M Co (NYSE:MMM) is something of an outlier. It offers everything from office supplies to healthcare products to the power transformers you see perched on top of power-line poles.It's wild mix that seems to work for 3M though, giving the company something to sell regardless of the economic environment.The clincher: 3M has managed to pay and increase its dividend every year going all the way back to 1977.Source: Shutterstock Walmart (WMT)Dividend Yield: 2.06% Year-to-date gain: 9.9%Yes, the advent of Amazon.com, Inc. (NASDAQ:AMZN) has proven problematic for the world's biggest retailer, Walmart Inc (NYSE:WMT). Rumors of Walmart's death at the hands of Amazon, however, have been greatly exaggerated.After being knocked over a few years ago, the company has regrouped, having figured out a way to fight the ever-growing reach of its online rival. The evidence? Last quarter's same-store sales grew 2.6%. Per-share profits missed estimates, to be clear, but much of that miss can be attributed to investments the retailer has been making in itself. * 7 Marijuana Companies: Which Pot Stocks Should You Buy? While it has been an ugly battle at times, Walmart has finally learned how to compete with Amazon.com. The fact that it can leverage its stores to do so only bolsters the bullish case. Southern Co (SO)Source: Shutterstock Dividend Yield: 4.74% Year-to-date gain: 19.6%No list of stocks to buy and hold forever would be complete without a utility stock. In good times and bad, consumers almost always pay their electricity bill. And, even though margins are thin and power providers don't have a ton of pricing power, they have little competition in most markets. Most requests for rate hikes are also approved without question.To that end, Southern Co (NYSE:SO) is one of the top picks of the litter.Southern serves nine million customers, mostly in the south, although it's represented in most of the major regions of the United States. More important, Southern Co has dished out stunningly consistent (even if tiny) profit growth, setting the stage for equally consistent dividends. It has not failed to increase its annual payout since the late 90's.Source: Shutterstock Johnson & Johnson (JNJ)Dividend Yield: 2.60% Year-to-date gain: 8.46%As advanced as we've become as a society, the need for medicines, surgical products and simple healthcare solutions like Band-Aids and Tylenol is never going to go away. That means Johnson & Johnson (NYSE:JNJ) -- which maintains a bigger product portfolio than most investors realize -- will always have something to sell to someone.That being said, don't think for a minute that a play on J&J is capitulation in the search for respectable growth. The company isn't just about treating tummy troubles and selling no-tears baby shampoo. * 7 AI Stocks to Watch with Strong Long-Term Narratives It still operates a pharmaceutical arm as well, with rheumatoid arthritis and Crohn's disease drug Remicade and blood-thinner Xarelto both driving more than $1 billion in annual sales for the company.Source: Shutterstock Berkshire Hathaway (BRK.B, BRK.A)Dividend Yield: N/A Year-to-date gain: 4.43%If the Warren Buffett mindset is the underlying philosophy in play here, why not go straight to the source and buy a piece of the fund he built from the ground up? That's Berkshire Hathaway Inc. (NYSE:BRK.B, NYSE:BRK.A).Sure, in his most recent letter to shareholders, the Oracle of Omaha said he's struggling to find new companies at a "sensible purchase price," which is the life-blood of the organization's growth. There's also the stark reality that the 87-year-old Buffett is increasingly less involved with Berkshire Hathaway. That separation is only going to widen as time marches on.Still, he has more than proven his way works for the long haul. Over the course of the past half-century, Berkshire stock has performed about twice as well as the S&P 500 has.Source: Shutterstock Waste Management (WM)Dividend Yield: 1.96% Year-to-date gain: 18%There's an old adage … the only two sure things in life are death and taxes.It's a humorous point about the limited nature of human life and the far-reaching power of the IRS. But, it's not necessarily a complete cliche. There's a third certainty. That is, as long as people are living on the planet earth, they'll be creating garbage to shuttle to their nearby landfill.Enter Waste Management, Inc. (NYSE:WM), which runs garbage-pickup services for 21 million North American customers. Although its top and bottom lines ebb and flow, the bigger trend for both is pointed upward. * 10 Dow Jones Stocks Holding the Blue Chip Index Back Look for more of the same too. As CEO Jim Fish pointed out late last month, "The babyboomers are coming into a period of heavy medical spend. All of our parents are aging and spending more on medical spend. There is medical waste generated from that, we are in that business. The industrial economy is important to us.Whether it's through repatriation from the new tax law, or just through the fact the U.S. and Canada are great places to do business and the industrial economy is showing some signs of life, we are a big industrial player on the back-end of the cycle."Source: Shutterstock American Water Works (AWK)Dividend Yield: 1.78% Year-to-date gain: 15.03%Perhaps just as certain as death, taxes and the creation of trash, as long as people are alive they're going to need water to survive. That puts a water utility name like American Water Works Company Inc (NYSE:AWK) in the catbird seat.Much like electricity providers Southern Company, American Water Works Company -- which offers water and sewer services to 15 million people in the United States -- is rarely told no when it wants to raise rates. Water service prices have risen at above-inflation rates for the past several years, and American Water Works Company has benefitted from that industry-wide trend. It's not apt to change anytime soon.Source: Shutterstock Colgate-Palmolive (CL)Dividend Yield: 2.50% Year-to-date gain: 16%Last but not least, while the purchase of things like cars are cyclical, and the automobile industry itself is subject to constant reinvention, there are some consumer goods people just buy over and over again without a second thought. Among those often-repurchased items are Colgate toothpaste, Palmolive dish soap, Speed Stick deodorant and Cuddly fabric conditioner.Yep, they're all made by Colgate-Palmolive Company (NYSE:CL), though they're only a small sampling of the brands you'll find under the company's umbrella. * 7 High-Risk Stocks With Big Potential Rewards Those who know the Colgate-Palmolive story well will know the company has gotten into some sloppy spending habits, crimping margins more than most shareholders would like. That's starting to change, however, with a serious and rather impressive cost-cutting initiative. The benefits of that work could last years, if not decades.As of this writing, James Brumley hold a long position in AT&T. You can follow him on Twitter, at @jbrumley.Compare Brokers The post 10 Best Stocks to Buy and Hold Forever appeared first on InvestorPlace.

  • Is More Downside Ahead for Boeing Stock? Should You Buy?
    InvestorPlace3 days ago

    Is More Downside Ahead for Boeing Stock? Should You Buy?

    The news surrounding Boeing (NYSE:BA) is no secret at this point. The 737 MAX has some serious issues that have resulted in massive backlash against the jet maker. To be honest, Boeing stock hasn't suffered as big of a blow as some would have thought, as support continues to lift BA.Source: Shutterstock Does that mean it's time to buy? Let's look at what's happening. Boeing's 737 MAX IssueLast fall, a 737 MAX operated by Lion Air crashed, killing all on board. There were concerns by pilots, but it didn't stop airlines from keeping the 737 MAX operating in their fleet. Another accident involving the 737 Max occurred in March, with Ethiopian Air suffering a crash, leaving no survivors.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Marijuana Companies: Which Pot Stocks Should You Buy? This caused the industry to awake from its slumber, with countries and airlines quickly grounding their 737 MAX fleet. This is a terrible optic for the aircraft manufacturer, and it's about to hit Boeing's bank account.For a moment, forget about the possible order cancellations, potentially lower prices and lawsuits Boeing will face. According to their first-quarter deliveries report, the company did not log one new order for the 737 MAX in March. This isn't some hokey jet at the bottom of its catalog, either. The MAX is Boeing's fastest-selling unit right now. For the order line to dry up instantly says everything about what the industry thinks about the embattled airplane.If the solution isn't a simple software fix, Boeing's sales and earnings could be at stake. Not that it will bankrupt the company, but it will cause some investors to rethink Boeing stock in the near term.More likely than not, BA will get through the 737 MAX issue in the same way that Johnson & Johnson (NYSE:JNJ), McDonald's (NYSE:MCD) or Disney (NYSE:DIS) and other blue-chip names get through issues like this. But that doesn't mean it may not suffer more before moving past it. Trading BA Stock Price Click to Enlarge The 737 MAX has become a short-term focus, but it could become a longer-term worry. That's why we're looking at two charts, the six-month daily (above) and a 30-month weekly chart (below). I have updated these charts from my prior outlook earlier this month.As you can see on the short-term chart, Boeing stock continues to bounce with each test of that $362-ish level. It's just above the 200-day moving average at $359, but BA stock is struggling to move higher. It put in a lower high earlier this month when it failed to reclaim the 50 DMA. If momentum fades here, it will secure another lower high and increase the odds that shares will break below support.Then what?That's where the longer-term chart comes into play. There's support in the low $360s, while the 50-week moving average is at $357. Click to Enlarge This 50-week/200-day combo should be enough to buoy Boeing stock on its first test. However, if there's a gap down below this level, BA stock may quickly find itself back in its prior range.This rangebound action persisted for most of 2018, keeping the Boeing stock price between $315 and $360. The occasional break below range support was met with buyers, and you can see how BA shares have been finding prior-range resistance as current support.If support does hold up, we need to see the Boeing stock price push through the 10-week moving average and get above its 50 DMA. Until then, a break below prior resistance/current support is a possibility. Bottom Line on BA StockBoeing stock will report earnings on April 24. It's hard to imagine investors finding a sudden wave of confidence ahead of that report. The only exception? Perhaps management giving the all-clear and global airlines announcing the re-addition of the 737 MAX to their fleet.Estimates currently call for revenue to grow 2.4% to $23.95 billion in the quarter, driving earnings of $3.59 per share. This EPS estimate calls for a 1.4% decline year-over-year, and has fallen from $4.30 per share over the last 30 days, a 16.5% decline.The full-year estimates have also come down, although not as much. Full-year expectations now call for earnings of $17.81 per share. This is down almost 12% over the past 30 days from $20.21 per share. However, this would represent growth of more than 11% YOY, while revenue is still expected to grow 4.6% for 2019.BA is still a cash flow machine. It runs a very profitable outfit and has a deep backlog of new orders. Even with the disruption to the 737 MAX, this backlog should remain robust and keep Boeing's long-term trajectory intact. That said, full-year estimates are perhaps the biggest risk to BA stock. If management comes out with a disappointing outlook or admits business-related headwinds, watch out! Covering analysts will likely cut their full-year expectations.If that happens, Boeing stock could come under pressure and fall below those key support levels we highlighted. Of course, the opposite is possible too.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy for Spring Season Growth * This Is How You Beat Back a Bear Market * 7 Dental Stocks to Buy That Will Make You Smile Compare Brokers The post Is More Downside Ahead for Boeing Stock? Should You Buy? appeared first on InvestorPlace.

  • CNBC4 days ago

    Dow stock that's lost $34 billion in market cap in the last week could be a buy, says investor

    Shares of health-care giant UnitedHealth have dropped considerably in the last week, but one market watcher advises betting on the dip.

  • 5 takeaways from Johnson & Johnson’s first-quarter results
    MarketWatch4 days ago

    5 takeaways from Johnson & Johnson’s first-quarter results

    Johnson & Johnson topped Wall Street’s earnings expectations on Tuesday, extending the company’s multiyear streak of delivering better-than-expected results.

  • InvestorPlace4 days ago

    Why The Rally In Johnson & Johnson Stock May Top Out At $150

    Shares of Johnson & Johnson (NYSE:JNJ) rallied recently after the consumer and pharmaceutical healthcare giant reported first quarter numbers that topped expectations, while also hiking its full-year revenue and profit guide. JNJ stock rose a few percentage points in response. The shares now trade near $140, up a healthy 15% from late 2018 lows.For a stock that's been range-bound between $120 and $150 for several years, the JNJ stock move toward $140 is an interesting move. Naturally, investors have to ask themselves here: How much longer can this rally last? Specifically, can JNJ stock finally breakout above $150 this time around?I'm not convinced. To be sure, Johnson & Johnson is a stable growth company trading at a stable growth valuation. But, growth is slowing as the global economy cools, and prices above $150 are only fundamentally supported for JNJ stock if growth accelerates from here.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat won't happen. As such, despite the strong beat and a higher guidance, I think that this 2019 rally in JNJ stock will ultimately top out at $150, much like previous rallies in the share have over the past two years. Stable Fundamentals But Not Getting BetterThe best way to describe the fundamentals underlying JNJ stock is that they are stable and healthy, but won't get much better anytime soon. * 10 Dow Jones Stocks Holding the Blue Chip Index Back Johnson & Johnson is a big business with lots of moving parts. But, at its core, there are three businesses here, and all three are supported by stable demand drivers. First, there's the consumer business, which sells health and wellness products that have historically proven to have stable demand. Second, you have the pharma business, which sells various medicines that consumers need, regardless of competitive landscape or economic backdrop. Third, you have the medical devices business, which is a necessary component in the stable demand healthcare industry.Overall, then, Johnson & Johnson is supported by three stable but low-growth businesses. That's why adjusted operational sales growth at the company has consistently run in the low- to high-single-digit range over the past several years, and also why margins have concurrently inched higher during that stretch.But, this year's guide calls for just 3% adjusted sales growth. That would be the second-lowest adjusted sales growth rate over the past five years. Further, adjusted profit growth is pegged around 7%. That, too, would mark one of the weakest profit growth years in recent memory.In other words, thanks to a global economic slowdown, Johnson & Johnson's numbers are getting slightly weaker. This slightly weaker growth profile should be the new norm going forward as we enter into the last few innings of this economic expansion. Ultimately -- and unfortunately -- slower growth may put a lid on the current rally in JNJ stock. $150 is a Fundamental and Technical TopThe level to watch for -- and be cautious of -- is $150.From a technical perspective, this has been JNJ's ceiling for the past two years. The big 2017 rally in JNJ stock was ultimately short-circuited when the stock got close to $150 in early 2018. Then, the big 2018 recovery rally in JNJ stock was likewise short-circuited when the stock again closed in on $150 in late 2018. * 8 Risky Stocks to Watch as Earnings Season Kicks Off The 2019 rally in Johnson & Johnson stock looks well on its way to $150. If history holds up, it will ultimately be short-circuited later this year when the share price approaches $150.Fundamentals say that history should hold up in 2019, and then break in 2020. Broadly speaking, Johnson & Johnson projects as a mid-single digit, 3-5% adjusted revenue grower over the next several years. During that stretch, profit margins should continue to expand, but at a slower pace than over the past five years given slower top-line growth. That combination of tepid revenue growth and some margin expansion should produce earnings-per-share of $13 by 2025.Based on a market average and historically average 16x forward multiple, that equates to a fiscal 2024 price target for JNJ stock of $208. Discounted back by 7% per year (three points below my normal 10% rate to account for the yield), that implies a reasonable fiscal 2019 price target of just under $150.As such, a price tag above $150 for Johnson & Johnson stock isn't fundamentally supported until 2020. Bottom Line on JNJ StockJohnson & Johnson is a fine company supported by healthy fundamentals. But, prices above $150 for JNJ stock aren't fundamentally supported until 2020. As such, this big 2019 rally in JNJ stock will ultimately top out around $150, much the big 2017 and 2018 rallies.As of this writing, Luke Lango did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy for Spring Season Growth * This Is How You Beat Back a Bear Market * 7 Dental Stocks to Buy That Will Make You Smile Compare Brokers The post Why The Rally In Johnson & Johnson Stock May Top Out At $150 appeared first on InvestorPlace.

  • Morningstar4 days ago

    Solid Drug Sales, Cost Control Boost Johnson & Johnson

    The first-quarter performance reinforces our wide moat rating.

  • Why ‘Scared’ Investors May Push Health Care Stocks Even Lower
    Investopedia4 days ago

    Why ‘Scared’ Investors May Push Health Care Stocks Even Lower

    While the broad market zooms ahead, health care stocks are being weighed down by regulatory threats even as earnings forecasts remain strong.

  • Asian shares edge lower despite encouraging China GDP data
    Associated Press4 days ago

    Asian shares edge lower despite encouraging China GDP data

    TOKYO (AP) — Major share benchmarks were mostly lower in Asia on Wednesday after China announced its economy grew at a 6.4% annual pace in the last quarter.

  • Associated Press4 days ago

    US halts sales of pelvic mesh tied to injuries in women

    WASHINGTON (AP) — U.S. health regulators on Tuesday halted sales of a type of surgical mesh used to repair pelvic conditions in women, following years of patients' reports of injuries and complications from the implants.

  • TheStreet.com4 days ago

    Johnson & Johnson and United Healthcare Face a Series of Obstacles

    The company also spent roughly $400 million in settlements related to Xarelto, a blood thinner. The problems created a quarter with decreases in earnings, but the company also had flat revenues. Compared to 2018's $20.01 billion, it marks a 0.1% increase year over year.

  • Associated Press4 days ago

    Qualcomm and Progressive jump while Wave Life Sciences drops

    Stocks that moved substantially or traded heavily on Tuesday: Qualcomm Corp., up $13.27 to $70.45 The mobile chip maker settled a long-running financial dispute with iPhone maker Apple. Johnson & Johnson, ...

  • What Happened in the Stock Market Today
    Motley Fool4 days ago

    What Happened in the Stock Market Today

    Johnson & Johnson's earnings results were better than expected, and UnitedHealth Group reported strong growth but stirred investor angst.

  • Stocks rise after strong earnings results
    Yahoo Finance4 days ago

    Stocks rise after strong earnings results

    Stocks rose Tuesday as a host of major companies reported quarterly results that beat Wall Street’s expectations.

  • Checking in on trade war's impact on the markets
    Yahoo Finance Video2 days ago

    Checking in on trade war's impact on the markets

    GuideStone Capital Management President David Spika joins Yahoo Finance's Adam Shapiro, Julie Hyman, Jared Blikre, and MIT Professor Sinan Aral.